Intravenous ketamine and progressive cholangiopathy in COVID-19 patients
Vincent Mallet, K Böck, Paul Doumbe Mandengue, Nicolas Dufour, Torsten Voigtlaender, Jean-Damien Ricard, Pierre Isnard, Vincent Frochot, Emmanuel Letavernier, Lucile Moga, Amandine Landrieux, Pierre‐Emmanuel Rautou, Nathalie Pons‐Kerjean, Anaïs Vallet‐Pichard, Laurent Chouchana, Coralie Gernez, Carole Burger, Anne Scemla, Christian de Tymoski, François Dépret, Emmanuel Dudoignon, Lionel Lamhaut, Rémi Flicoteau, G. Rousseau, Jean–Paul Duong Van Huyen, Jean-Michel Corréas, Heiner Wedemeyer, Stanislas Pol
Topics & Concepts
KetamineMedicineCoronavirus disease 2019 (COVID-19)ARDSSedationPandemicAnesthesiaAcute respiratory distressMechanical ventilationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug2019-20 coronavirus outbreakRespiratory distressInfectious disease (medical specialty)Intensive care medicineDiseaseInternal medicineLungPharmacologyVirologyOutbreakIntensive Care Unit Cognitive DisordersAnesthesia and Sedative AgentsLong-Term Effects of COVID-19